{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Ren Y"],"funding":["Top Talent Support Program for young and middle-aged people of Wuxi Health Committee","Traditional Chinese Medicine Research Project of Wuxi Health Committee","National Natural Science Foundation of China","China Postdoctoral Science Foundation","Talent Support Program for young and middle-aged people of Wuxi Health Committee"],"pagination":["739"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9920828"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["15(3)"],"pubmed_abstract":["Ulcerative colitis (UC), one of the typical inflammatory bowel diseases caused by dysregulated immunity, still requires novel therapeutic medicine with high efficacy and low toxicity. <i>Hericium erinaceus</i> has been widely used to treat different health problems especially gastrointestinal sickness in China for thousands of years. Here, we isolated, purified, and characterized a novel low weight polysaccharide (HEP10, Mw: 9.9 kDa) from the mycelia of <i>H. erinaceus</i> in submerged culture. We explored the therapeutic effect of HEP10 on UC and explored its underlying mechanisms. On one hand, HEP10 suppressed the production of TNF-α, IL-1β, IL-6, inducible iNOS, and COX-2 in LPS challenged murine macrophage RAW264.7 cells, as well as in colons from DSS-induced colitis mice. On the other hand, HEP10 treatment markedly suppressed the activation of NLRP3 inflammasome, NF-κB, AKT, and MAPK pathways. Moreover, HEP10 reversed DSS-induced alternation of the gut community composition and structure by significantly increasing <i>Akkermansia muciniphila</i> and also promoting functional shifts in gut microbiota. Structural equation modeling also highlighted that HEP10 can change widely through gut microbiota. In conclusion, HEP10 has a better prebiotic effect than the crude polysaccharides of <i>H. erinaceus</i>, which can be used as a novel dietary supplement and prebiotic to ameliorate colitis."],"journal":["Nutrients"],"pubmed_title":["Low Weight Polysaccharide of <i>Hericium erinaceus</i> Ameliorates Colitis via Inhibiting the NLRP3 Inflammasome Activation in Association with Gut Microbiota Modulation."],"pmcid":["PMC9920828"],"funding_grant_id":["32001661","32101964","31970746","ZYKJ201910","2018M640455","HB2020055"],"pubmed_authors":["Zhou L","Li H","Sheng Y","Yu L","Ren Y","Lu Z","Guan T","Xue Y","Li W","Gao R","Sun Q","Geng Y","Liu C","Shi J","Xu Z"],"additional_accession":[]},"is_claimable":false,"name":"Low Weight Polysaccharide of <i>Hericium erinaceus</i> Ameliorates Colitis via Inhibiting the NLRP3 Inflammasome Activation in Association with Gut Microbiota Modulation.","description":"Ulcerative colitis (UC), one of the typical inflammatory bowel diseases caused by dysregulated immunity, still requires novel therapeutic medicine with high efficacy and low toxicity. <i>Hericium erinaceus</i> has been widely used to treat different health problems especially gastrointestinal sickness in China for thousands of years. Here, we isolated, purified, and characterized a novel low weight polysaccharide (HEP10, Mw: 9.9 kDa) from the mycelia of <i>H. erinaceus</i> in submerged culture. We explored the therapeutic effect of HEP10 on UC and explored its underlying mechanisms. On one hand, HEP10 suppressed the production of TNF-α, IL-1β, IL-6, inducible iNOS, and COX-2 in LPS challenged murine macrophage RAW264.7 cells, as well as in colons from DSS-induced colitis mice. On the other hand, HEP10 treatment markedly suppressed the activation of NLRP3 inflammasome, NF-κB, AKT, and MAPK pathways. Moreover, HEP10 reversed DSS-induced alternation of the gut community composition and structure by significantly increasing <i>Akkermansia muciniphila</i> and also promoting functional shifts in gut microbiota. Structural equation modeling also highlighted that HEP10 can change widely through gut microbiota. In conclusion, HEP10 has a better prebiotic effect than the crude polysaccharides of <i>H. erinaceus</i>, which can be used as a novel dietary supplement and prebiotic to ameliorate colitis.","dates":{"release":"2023-01-01T00:00:00Z","publication":"2023 Feb","modification":"2026-04-08T14:15:21.356Z","creation":"2025-02-19T02:23:48.535Z"},"accession":"S-EPMC9920828","cross_references":{"pubmed":["36771444"],"doi":["10.3390/nu15030739"]}}